PT - JOURNAL ARTICLE AU - Minji Jennifer Kim AU - Nicholas Jones AU - Laura R Steeples TI - Miliary tuberculosis developing during adalimumab treatment for Behçet’s disease with uveitis AID - 10.1136/bcr-2018-226772 DP - 2018 Nov 01 TA - BMJ Case Reports PG - e226772 VI - 11 IP - 1 4099 - http://casereports.bmj.com/content/11/1/e226772.short 4100 - http://casereports.bmj.com/content/11/1/e226772.full SO - BMJ Case Reports2018 Nov 01; 11 AB - Tumour necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine in non-infective uveitis (NIU). Adalimumab, an anti-TNF-α monoclonal antibody, is approved for the treatment of severe NIU by the European Medicines Agency. There is a recognised risk of serious infections, including tuberculosis (TB), during anti-TNF-α therapy in systemic immune-mediated diseases. We describe miliary pulmonary TB during adalimumab therapy for severe NIU. To our knowledge, this is the first detailed report of this complication in a patient with uveitis. We present the challenges of managing vision-threatening uveitis during life-threatening infection necessitating withdrawal of adalimumab and oral immunosuppression therapy. Uveitis activity was controlled during anti-TB therapy with oral corticosteroid therapy.